Core Viewpoint - BGM Group's stock has shown a positive trend with a 2.11% increase, reflecting investor interest despite a significant drop in net profit [1] Financial Performance - As of March 31, 2025, BGM Group reported total revenue of $14.31 million, representing a year-on-year growth of 13.92% [1] - The company's net profit attributable to shareholders was -$0.8612 million, indicating a year-on-year decrease of 307.79% [1] Company Overview - BGM Group, formerly known as Qilian International Holdings Group, is headquartered in Chengdu, China, and focuses on the biopharmaceutical, biorefining, and healthcare sectors [1] - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium [1] - Tetracycline raw materials are used for producing human antibiotics and supporting global aquaculture and livestock industries [1] - Crude heparin sodium is processed into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1] - Licorice preparations, such as compound licorice tablets, are used as cough remedies and supplied to retail pharmacies [1]
博美集团上涨2.11%，报7.73美元/股，总市值14.22亿美元